Seres Therapeutics, Inc. (NASDAQ:MCRB) Expected To Report Earnings On Thursday

Ivan Schwartz
March 21, 2017

(MCRB). The consensus rating is 1.9, indicating analysts in general look favorably on the company's future prospects.

SER-109, an oral capsule, is Seres' lead Ecobiotic microbiome therapeutic for the treatment of multiply recurrent C. difficile infection.

Signaling a rapid turnaround after faltering last July from a failed Phase 2 trial of SER-109 to treat recurrent Clostridium difficile infection, microbiome-therapy pioneer Seres Therapeutics said March 16 it will initiate a redesigned SER-109 clinical study with a nod from the Food and Drug Administration.

For this year, Seres Therapeutics, Inc.

Seres Therapeutics, Inc. (NASDAQ:MCRB): On Thursday heightened volatility was witnessed in Seres Therapeutics, Inc. The average twelve-month price target among analysts that have updated their coverage on the stock in the a year ago is $23.20. Finally, Cowen and Company reiterated a "buy" rating on shares of Seres Therapeutics in a research note on Wednesday, February 1st.

Many research firms have provided their ratings on Seres Therapeutics, Inc.

Uber president sticks the knife in as he quits after six months
But for the most part, he found his experience with smaller ride-sharing apps, Fasten and RideAustin, to be perfectly adequate. One will investigate her claims specifically, the other is conducting a broader investigation into Uber's workplace practices.

North Korea tests powerful rocket engine
Officials on both sides said North Korea dominated the discussions as two countries believe the situation reached unsafe levels. Diplomatic sources told VOA the meeting from April 6-7 will take place at Trump's Mar-a-Lago resort in Florida.

SC to auto makers: Give details of unsold BS-III vehicles
In October a year ago , EPCA directed vehicle manufacturers that no non-BS-IV vehicle will be registered after April 1. With the BS-IV norms just around the corner, this might be a good time to keep an eye on the stock clearance sales.

As of current trade, Seres Therapeutics Inc (NASDAQ:MCRB) has shown weekly upbeat performance of 35.50%. The last close places the company's stock about $23.27 off its 52 week high of $35.98 and $4.66 above the 52 week low of $8.05.

Seres Health, Inc. has a 50 day moving average of 9.69 and a 200 day moving average of 10.73.

A number of equities analysts recently weighed in on the stock.

They expect $-0.7 EPS, down 41.43% or $0.29 from last year's $-0.41 per share. Now 12.9% of the stock's total float is wrapped up in these bearish bets, representing roughly four weeks' worth of buying power, at MCRB's average daily pace. The company reported ($0.63) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.70) by $0.07. The business earned $3 million during the quarter, compared to the consensus estimate of $3 million. Fidelity Management and Research Company is the second biggest holder with 6 million shares now valued at 60.47 million whilst Federated Global Inv Mgmt Corp has 2 million shares valued at 25.12 million. But with the equity now in the red on a year-to-date basis, a round of downbeat brokerage attention could spell even more trouble. Renaissance Technologies LLC now owns 400,300 shares of the company's stock worth $3,963,000 after buying an additional 103,800 shares during the last quarter. ARK Investment Management LLC acquired a new stake in Seres Therapeutics during the fourth quarter worth about $4,871,000.

Total shares held by institutions as of the most recent company filings are 29,846,468 with a reported 13,141,724 bought and 1,329,518 sold. The increase in fourth quarter net loss was driven primarily by continued growth in clinical and development expenses as well as increased headcount, and ongoing development of the company's microbiome therapeutics platform. "Our prior SER-109 studies provided important new biological and clinical data that have advanced our pioneering microbiome therapeutic efforts".

Other reports by GizPress

Discuss This Article